The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer

Neoadjuvant chemotherapy may decrease tumor volume to allow breast conservation surgery. Its effect on estrogen and progesterone receptor (ER/PR) expression and hormone receptor (HR) status is controversial. From February 2001 to July 2002, 56 breast cancer patients treated with neoadjuvant chemothe...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of surgery 2003-10, Vol.186 (4), p.348-350
Main Authors: Lee, Susan H, Chung, Maureen A, Quddus, M.Ruhul, Steinhoff, Margaret M, Cady, Blake
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Biopsy
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - surgery
Cancer therapies
Chemotherapy
Chemotherapy, Adjuvant
Cytotoxicity
Female
Hormone receptor status
Humans
Medical sciences
Neoadjuvant chemotherapy
Neoadjuvant Therapy
Pharmacology. Drug treatments
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neoadjuvant chemotherapy may decrease tumor volume to allow breast conservation surgery. Its effect on estrogen and progesterone receptor (ER/PR) expression and hormone receptor (HR) status is controversial. From February 2001 to July 2002, 56 breast cancer patients treated with neoadjuvant chemotherapy and 56 non-neoadjuvant therapy (control) patients with adequate tissue samples were identified. Quantitative ER/PR expression was analyzed in preneoadjuvant or preoperative core biopsies and final surgical specimens. Changes between the two groups were compared to determine if alterations were due to neoadjuvant chemotherapy or tissue sampling. The ER/PR expression changed in 34 (61%) neoadjuvant chemotherapy patients and 27 (48%) control patients. These expression changes resulted in HR status (positive/negative) alterations in 3 patients (5%) in both groups. Age, histology, chemotherapy regimen, and neoadjuvant response did not predict change. Hormone receptor status changed in 5% of neoadjuvant chemotherapy and control groups due to tissue sampling. As these changes may impact treatment, HR expression reanalysis in final surgical specimens is recommended.
ISSN:0002-9610
1879-1883
DOI:10.1016/S0002-9610(03)00271-X